<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34912047</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2399-3642</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Communications biology</Title><ISOAbbreviation>Commun Biol</ISOAbbreviation></Journal><ArticleTitle>Novel chemical inhibitor against SOD1 misfolding and aggregation protects neuron-loss and ameliorates disease symptoms in ALS mouse model.</ArticleTitle><Pagination><StartPage>1397</StartPage><MedlinePgn>1397</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1397</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s42003-021-02862-z</ELocationID><Abstract><AbstractText>Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by selective death of motor neurons. Mutations in Cu, Zn-superoxide dismutase (SOD1) causing the gain of its toxic property are the major culprit of familial ALS (fALS). The abnormal SOD1 aggregation in the motor neurons has been suggested as the major pathological hallmark of ALS patients. However, the development of pharmacological interventions against SOD1 still needs further investigation. In this study, using ELISA-based chemical screening with wild and mutant SOD1 proteins, we screened a new small molecule, PRG-A01, which could block the misfolding/aggregation of SOD1 or TDP-43. The drug rescued the cell death induced by mutant SOD1 in human neuroblastoma cell line. Administration of PRG-A01 into the ALS model mouse resulted in significant improvement of muscle strength, motor neuron viability and mobility with extended lifespan. These results suggest that SOD1 misfolding/aggregation is a potent therapeutic target for SOD1 related ALS.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>Tae-Gyun</ForeName><Initials>TG</Initials><Identifier Source="ORCID">0000-0002-6957-0998</Identifier><AffiliationInfo><Affiliation>Department of Molecular Biology, College of Natural Science, Pusan National University, Busan, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rare Disease R&amp;D Center, PRG S&amp;T Co., Ltd, Busan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Min-Ho</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, College of Natural Science, Pusan National University, Busan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>So-Mi</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, College of Natural Science, Pusan National University, Busan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Soyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, College of Natural Science, Pusan National University, Busan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Jung-Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, College of Natural Science, Pusan National University, Busan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Young Jun</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, College of Natural Science, Pusan National University, Busan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Jinsook</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Food Science, College of Agricultural and Life Sciences, Seoul National University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Hyewon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Agricultural Biotechnology, Seoul National University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Yun-Jeong</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Agricultural Biotechnology, Seoul National University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Eui-Man</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-1145-402X</Identifier><AffiliationInfo><Affiliation>Department of Molecular Biology, College of Natural Science, Pusan National University, Busan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ha</LastName><ForeName>Nam-Chul</ForeName><Initials>NC</Initials><Identifier Source="ORCID">0000-0003-4813-748X</Identifier><AffiliationInfo><Affiliation>Department of Food Science, College of Agricultural and Life Sciences, Seoul National University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Bae-Hoon</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, College of Natural Science, Pusan National University, Busan, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rare Disease R&amp;D Center, PRG S&amp;T Co., Ltd, Busan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Yonghoon</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-3252-7846</Identifier><AffiliationInfo><Affiliation>Department of Agricultural Biotechnology, Seoul National University, Seoul, Republic of Korea. y_kwon@snu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Bum-Joon</ForeName><Initials>BJ</Initials><Identifier Source="ORCID">0000-0002-6037-7219</Identifier><AffiliationInfo><Affiliation>Department of Molecular Biology, College of Natural Science, Pusan National University, Busan, Republic of Korea. bjark1219@pusan.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rare Disease R&amp;D Center, PRG S&amp;T Co., Ltd, Busan, Republic of Korea. bjark1219@pusan.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Commun Biol</MedlineTA><NlmUniqueID>101719179</NlmUniqueID><ISSNLinking>2399-3642</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="Y">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34912047</ArticleId><ArticleId IdType="pmc">PMC8674338</ArticleId><ArticleId IdType="doi">10.1038/s42003-021-02862-z</ArticleId><ArticleId IdType="pii">10.1038/s42003-021-02862-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunton-Stasyshyn RK, Saccon RA, Fratta P, Fisher EM. SOD1 function and its implications for amyotrophic lateral sclerosis pathology: new and renascent themes. Neuroscientist. 2015;21:519&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">25492944</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 2017;3:1&#x2013;19.</Citation></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617.</Citation><ArticleIdList><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso M, et al. Mutant copper-zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in astrocytes: implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis. J. Biol. Chem. 2013;288:15699&#x2013;15711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3668729</ArticleId><ArticleId IdType="pubmed">23592792</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997;18:327&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasil AA, et al. Implications of fALS mutations on Sod1 function and oligomerization in cell models. Mol. Neurobiol. 2018;55:5269&#x2013;5281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948255</ArticleId><ArticleId IdType="pubmed">28884318</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J. Neurol. Neurosurg. Psychiatry. 2010;81:1324&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988617</ArticleId><ArticleId IdType="pubmed">20861059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji A, Zhang X, Chen W, Huang W. Genetics insight into the amyotrophic lateral sclerosis/frontotemporal dementia spectrum. J. Med. Genet. 2017;54:145&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">28087719</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci. 2010;13:1396&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="pubmed">20953194</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall D, Baloh RH. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J. Clin. Invest. 2017;127:3250&#x2013;3258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669558</ArticleId><ArticleId IdType="pubmed">28737506</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokrishevsky E, et al. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PloS ONE. 2012;7:e35050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3320864</ArticleId><ArticleId IdType="pubmed">22493728</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat. Neurosci. 2018;21:552&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat. Rev. Neurosci. 2015;16:109&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4312418</ArticleId><ArticleId IdType="pubmed">25588378</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Durazo A, Whitelegge JP, Borchelt DR. An examination of wild-type SOD1 in modulating the toxicity and aggregation of ALS-associated mutant SOD1. Hum. Mol. Genet. 2010;19:4774&#x2013;4789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989888</ArticleId><ArticleId IdType="pubmed">20871097</ArticleId></ArticleIdList></Reference><Reference><Citation>Graffmo KS, et al. Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis. Hum. Mol. Genet. 2013;22:51&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">23026746</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad LI, et al. Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. Proc. Natl Acad. Sci. USA. 2014;111:3620&#x2013;3625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3948312</ArticleId><ArticleId IdType="pubmed">24550511</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, et al. Superoxide dismutase 1 and tgSOD1G93A mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis. PLoS ONE. 2010;5:e10627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2869360</ArticleId><ArticleId IdType="pubmed">20498711</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaarsma D, et al. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Neurobiol. Dis. 2000;7:623&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">11114261</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Tokuda E. Does wild-type Cu/Zn-superoxide dismutase have pathogenic roles in amyotrophic lateral sclerosis? Transl. Neurodegeneration. 2020;9:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437001</ArticleId><ArticleId IdType="pubmed">32811540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon GS, et al. Pathological modification of TDP-43 in amyotrophic lateral sclerosis with SOD1 mutations. Mol. Neurobiol. 2019;56:2007&#x2013;2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6394608</ArticleId><ArticleId IdType="pubmed">29982983</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen PH, et al. Amyloid oligomers: a joint experimental/computational perspective on Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, type II diabetes, and amyotrophic lateral sclerosis. Chem. Rev. 2021;121:2545&#x2013;2647.</Citation><ArticleIdList><ArticleId IdType="pubmed">33543942</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S, Velde CV, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkler C, et al. Aggregated SOD1 causes selective death of cultured human motor neurons. Sci. Rep. 2018;8:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6219543</ArticleId><ArticleId IdType="pubmed">30401824</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Cleveland DW. Prion-like spread of protein aggregates in neurodegeneration. J. Exp. Med. 2012;209:889&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348110</ArticleId><ArticleId IdType="pubmed">22566400</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C, et al. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 2011;121:715&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026723</ArticleId><ArticleId IdType="pubmed">21245577</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body&#x2013;like pathology in long-term embryonic nigral transplants in Parkinson&#x2019;s disease. Nat. Med. 2008;14:504&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391962</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, et al. Lewy bodies in grafted neurons in subjects with Parkinson&#x2019;s disease suggest host-to-graft disease propagation. Nat. Med. 2008;14:501&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391963</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science. 2010;330:980&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Kim H. Prion-like mechanism in amyotrophic lateral sclerosis: are protein aggregates the key? Exp. Neurobiol. 2015;24:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4363329</ArticleId><ArticleId IdType="pubmed">25792864</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho C, Woo JS, Perez CF, Lee EH. A focus on extracellular Ca 2 entry into skeletal muscle. Exp. Mol. Med. 2017;49:e378&#x2013;e378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5628281</ArticleId><ArticleId IdType="pubmed">28912570</ArticleId></ArticleIdList></Reference><Reference><Citation>Brini M, Cal&#xec; T, Ottolini D, Carafoli E. Neuronal calcium signaling: function and dysfunction. Cell. Mol. life Sci. 2014;71:2787&#x2013;2814.</Citation><ArticleIdList><ArticleId IdType="pubmed">24442513</ArticleId></ArticleIdList></Reference><Reference><Citation>Juarez JC, et al. Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc. Natl Acad. Sci. USA. 2008;105:7147&#x2013;7152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438219</ArticleId><ArticleId IdType="pubmed">18480265</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukai T, Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid. Redox Signal. 2011;15:1583&#x2013;1606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3151424</ArticleId><ArticleId IdType="pubmed">21473702</ArticleId></ArticleIdList></Reference><Reference><Citation>PIRET J, Mottet D, Raes M, Michiels C. CoCl2, a chemical inducer of hypoxia&#x2010;inducible factor&#x2010;1, and hypoxia reduce apoptotic cell death in hepatoma cell line HepG2. Ann. N. Y. Acad. Sci. 2002;973:443&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">12485908</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier, M. et al. A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. Sci. Transl. Med. 10, 10.1126/scitranslmed.aah3924 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30518612</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, et al. Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells. Oncogene. 2010;29:4576&#x2013;4587.</Citation><ArticleIdList><ArticleId IdType="pubmed">20531295</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo TG, et al. Anti-cancer effect of novel PAK1 inhibitor via induction of PUMA-mediated cell death and p21-mediated cell cycle arrest. Oncotarget. 2017;8:23690&#x2013;23701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5410337</ArticleId><ArticleId IdType="pubmed">28423593</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist BG, Hare DJ, Double KL. A proposed mechanism for neurodegeneration in movement disorders characterized by metal dyshomeostasis and oxidative stress. Cell Chem. Biol. 2018;25:807&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">29861271</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu PH, et al. Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc. Natl Acad. Sci. USA. 1996;93:3155&#x2013;3160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39778</ArticleId><ArticleId IdType="pubmed">8610185</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill C, et al. SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALS. Sci. Rep. 2019;9:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6491559</ArticleId><ArticleId IdType="pubmed">31040321</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SH, et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 2013;16:571&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637847</ArticleId><ArticleId IdType="pubmed">23542689</ArticleId></ArticleIdList></Reference><Reference><Citation>Farah CA, Nguyen M, Julien J, Leclerc N. Altered levels and distribution of microtubule&#x2010;associated proteins before disease onset in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2003;84:77&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">12485403</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi H, Doh-ura K, Kawashima T, Kira J, Iwaki T. Immunohistochemical analysis of spinal cord lesions in amyotrophic lateral sclerosis using microtubule-associated protein 2 (MAP2) antibodies. Acta Neuropathol. 1999;97:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">9930890</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera ND, et al. Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models. PloS ONE. 2014;9:e90449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3942426</ArticleId><ArticleId IdType="pubmed">24595038</ArticleId></ArticleIdList></Reference><Reference><Citation>Seijffers R, et al. ATF3 expression improves motor function in the ALS mouse model by promoting motor neuron survival and retaining muscle innervation. Proc. Natl Acad. Sci. USA. 2014;111:1622&#x2013;1627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910594</ArticleId><ArticleId IdType="pubmed">24474789</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T, Kiernan MC. Riluzole, disease stage and survival in ALS. Lancet Neurol. 2018;17:385&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">29525493</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheah B, Vucic S, Krishnan A, Kiernan M. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr. Med. Chem. 2010;17:1942&#x2013;1959.</Citation><ArticleIdList><ArticleId IdType="pubmed">20377511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Iwasaki Y. Edaravone, a free radical scavenger, delayed symptomatic and pathological progression of motor neuron disease in the wobbler mouse. PLoS ONE. 2015;10:e0140316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4607459</ArticleId><ArticleId IdType="pubmed">26469273</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J, et al. Long&#x2010;term edaravone efficacy in amyotrophic lateral sclerosis: post&#x2010;hoc analyses of Study 19 (MCI186&#x2010;19) Muscle Nerve. 2020;61:218&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7004197</ArticleId><ArticleId IdType="pubmed">31621933</ArticleId></ArticleIdList></Reference><Reference><Citation>Chattopadhyay M, et al. The disulfide bond, but not zinc or dimerization, controls initiation and seeded growth in amyotrophic lateral sclerosis-linked Cu,Zn superoxide dismutase (SOD1) fibrillation. J. Biol. Chem. 2015;290:30624&#x2013;30636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4683282</ArticleId><ArticleId IdType="pubmed">26511321</ArticleId></ArticleIdList></Reference><Reference><Citation>Banci L, et al. Metal-free superoxide dismutase forms soluble oligomers under physiological conditions: a possible general mechanism for familial ALS. Proc. Natl Acad. Sci. USA. 2007;104:11263&#x2013;11267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1899188</ArticleId><ArticleId IdType="pubmed">17592131</ArticleId></ArticleIdList></Reference><Reference><Citation>Oztug Durer ZA, et al. Loss of metal ions, disulfide reduction and mutations related to familial ALS promote formation of amyloid-like aggregates from superoxide dismutase. PloS ONE. 2009;4:e5004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659422</ArticleId><ArticleId IdType="pubmed">19325915</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353:603&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444917</ArticleId><ArticleId IdType="pubmed">27493188</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe5;nberg A, et al. Altered perivascular fibroblast activity precedes ALS disease onset. Nat. Med. 2021;27:640&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">33859435</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Cleveland DW. The seeds of neurodegeneration: prion-like spreading in ALS. Cell. 2011;147:498&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220614</ArticleId><ArticleId IdType="pubmed">22036560</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng C, Trojanowski JQ, Lee VM. Protein transmission in neurodegenerative disease. Nat. Rev. Neurol. 2020;16:199&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">32203399</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, et al. Human alpha-synuclein-harboring familial Parkinson&#x2019;s disease-linked Ala-53 -&gt; Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. USA. 2002;99:8968&#x2013;8973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124407</ArticleId><ArticleId IdType="pubmed">12084935</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder SW, et al. Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 1994;67:1216&#x2013;1228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1225478</ArticleId><ArticleId IdType="pubmed">7811936</ArticleId></ArticleIdList></Reference><Reference><Citation>Haggerty T, et al. Hyperphosphorylated Tau in an &#x3b1;&#x2010;synuclein&#x2010;overexpressing transgenic model of Parkinson&#x2019;s disease. Eur. J. Neurosci. 2011;33:1598&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086951</ArticleId><ArticleId IdType="pubmed">21453448</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG. Propagation of Tau aggregates. Mol. brain. 2017;10:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5450399</ArticleId><ArticleId IdType="pubmed">28558799</ArticleId></ArticleIdList></Reference><Reference><Citation>Shammas SL, et al. A mechanistic model of tau amyloid aggregation based on direct observation of oligomers. Nat. Commun. 2015;6:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4421837</ArticleId><ArticleId IdType="pubmed">25926130</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>